By Michael Gwarisa The Medicines Control Authority of Zimbabwe (MCAZ) has announced the expedited approval of Lenacapavir, an innovative long-acting medicine for pre exposure prophylaxis (PrEP) to prevent HIV-1 infection. The MCAZ Director-General, Mr. Richard T. Rukwata, said “the rapid approval of Lenacapavir reflects the Authority’s dedication to accelerating access to trusted, high-quality health products and brings new hope for HIV prevention while reinforcing its commitment to safeguarding public health.” Lenacapavir was assessed and approved by the Registration Committee under the expedited review process, as it is considered to be…
Read MoreZimbabwe’s Medicines Regulatory Body Registers Lencapavir
